{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-110878","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.270393+00:00","generated_at":"2026-05-16T20:02:32.757911+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Emmaus Q3 net loss $2.1M; revenue down 38% YoY to $3.4M on generic competition","bullets":["Net loss of $2.1M ($0.03/share) vs net income of $1.8M in Q3 2024.","Revenue fell 38% to $3.4M from $5.5M; decline driven by generic L-Glutamine in U.S. and lower MENA sales.","Operating expenses reduced 43% to $2.4M due to workforce reduction and cost cuts.","Income from operations $0.7M vs $0.8M prior year, partially offsetting revenue drop.","Cash and equivalents dropped to $0.3M at Sept 30 from $1.4M at Dec 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-110878","json":"https://secwatch.observer/filing/0001213900-25-110878.json","markdown":"https://secwatch.observer/filing/0001213900-25-110878.md","text":"https://secwatch.observer/filing/0001213900-25-110878.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390025110878/0001213900-25-110878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390025110878/ea0265516-8k_emmaus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:02:32.757911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}